carecentrix

Provider Newsflash Sept 17, 2019

FDA RECALL

Purpose of this communication:

We are writing to inform you that effective immediately the FDA has issued a recall notice by Takeda Pharmaceutical Company, Ltd for all doses of Natpara (parathyroid hormone) for Injection (25 mcg, 50 mcg, 75 mcg, and 100 mcg) due to the potential for rubber particulates originating from the rubber septum of the Natpara cartridge becoming detached into the cartridge during the 14 day treatment.

What do I need to do?

- Please review the following recall notice:
- https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/takeda-issues-us-recall-natparar-parathyroid-hormone-injection-due-potential-rubber-particulate?utm_campaign=FDA%20MedWatch%20-%20Natpara%20%28parathyroid%20hormone%29%20for%20Injection%20by%20Takeda&utm_medium=email&utm_source=Eloqua
- Notify impacted patients and facilitate the repair, replacement and/or resolution of the recall, according to the guidelines issued by the manufacturer in the FDA notification.
- Confirm if you have any CareCentrix patients affected by this recall and notify the CareCentrix Quality Department by:
    - Faxing information– To: 919-792-6718 Attn: Quality Department

Thank you for your prompt attention and cooperation in this matter.